Maureen Canavan, PhD, MPH
Associate Research Scientist (General Medicine)Cards
About
Titles
Associate Research Scientist (General Medicine)
Affiliated Faculty, Yale Institute for Global Health
Biography
Maureen E. Canavan, Ph.D., is an epidemiologist at Yale Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) since 2017. In addition to working the MCBS data, she works as part of the Yale Cancer Center’s Cancer Care Innovations Lab (CaCIL) team evaluating quality metrics for cancer care. Her research interests include health management, employment, and end of life care. Prior to her work at COPPER, she was a member of the Global Health Leadership Institute (GHLI) team, she conducts qualitative and quantitative data analysis of GHLI studies in countries including Ghana, Ethiopia and China. She received an M.P.H. from the University of Medicine and Dentistry of New Jersey, School of Public Health and a B.S. from Pennsylvania State University.
Last Updated on May 21, 2025.
Appointments
General Internal Medicine
Associate Research ScientistPrimary
Other Departments & Organizations
- COPPER Center
- General Internal Medicine
- Internal Medicine
- Obesity Research Working Group
- Yale Institute for Global Health
Education & Training
- PhD
- Yale University Graduate School (2011)
- MPH
- University of Medicine and Dentistry of New Jersey, School of Public Health, Epidemiology, Health Education, and Behavioral Science (2005)
- BS
- Pennsylvania State University, Biology (2003)
Research
Publications
2025
Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality.
Canavan ME, Cheng L, Xiang JJ, Lin JK, Hui D, Zhao H, Nortje N, Ratan R, Cherny N, Pham T, Giordano SH, Niu J, Adelson KB. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. J Clin Oncol 2025, 43: 3391-3402. PMID: 41004691, DOI: 10.1200/JCO-25-00530.Peer-Reviewed Original ResearchThis study investigates the impact of systemic anticancer therapy near the end of life on healthcare and hospice for older adults, showing increased acute care utilization and decreased hospice use, highlighting the need for improved end-of-life care guidelines.Impact of a standardized multi-level review of anti-cancer therapy ordered for hospitalized individuals with solid tumors.
Westvold S, Shevlin C, Canavan M, Strait M, Abdelghany O, Carafeno T, Flanagan B, Merl M, Mitchell T, Carusillo N, Morris J, Gross C, Huntington S. Impact of a standardized multi-level review of anti-cancer therapy ordered for hospitalized individuals with solid tumors. JCO Oncology Practice 2025, 21: 477-477. DOI: 10.1200/op.2025.21.10_suppl.477.Peer-Reviewed Original ResearchSystemic anti-cancer therapyEnd-of-lifeDay of deathBedside nursing assessmentHospitalized patientsProportion of decedentsAnti-cancer therapySolid tumorsQuality of lifeNursing assessmentPhysician reviewPoisson regressionBenefits of treatmentCommittee reviewFisher's exact testPatient daysOrder rateSolid tumor patientsTreatment risksDecedentsExact testPhysiciansPharmacyTime periodsPatientsReal-World Perioperative Outcomes of Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-World Perioperative Outcomes of Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer. JTCVS Open 2025 DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsMortality Risk and Cause of Death Associated with Removal of the Adult Thymus: Analysis of the US Thymoma Population
Resio B, Canavan M, Caturegli G, Detterbeck F, Boffa D. Mortality Risk and Cause of Death Associated with Removal of the Adult Thymus: Analysis of the US Thymoma Population. Journal Of Thoracic Oncology 2025 PMID: 40865907, DOI: 10.1016/j.jtho.2025.08.017.Peer-Reviewed Original ResearchSurveillance Epidemiology and End ResultsNational Cancer DatabaseDuctal carcinoma in situPropensity-matched patientsThyroid cancerAdult thymusU.S. populationImmunologic end pointsCarcinoma in situFive-year survivalCancer incidencePartial thymectomyThyroid lobectomyResected breastLonger-term outcomesPartial mastectomyThyroid neoplasmsTotal thymectomyCancer DatabaseCause of deathNo significant differenceSecondary cancersSmall thymomaThymectomyEnd ResultsHypertensive Disorders of Pregnancy and Breastfeeding Among US Women
Nardella D, Canavan M, Taylor S, Sharifi M. Hypertensive Disorders of Pregnancy and Breastfeeding Among US Women. JAMA Network Open 2025, 8: e2521902. PMID: 40679825, PMCID: PMC12274979, DOI: 10.1001/jamanetworkopen.2025.21902.Peer-Reviewed Original ResearchConceptsPrevention's Pregnancy Risk Assessment Monitoring SystemAssociated with higher oddsBreastfeeding cessationCross-sectional studyPostpartum womenHypertensive disordersHigher oddsSelf-reported high blood pressurePregnancy Risk Assessment Monitoring SystemCenters for Disease Control and Prevention's Pregnancy Risk Assessment Monitoring SystemBreastfeeding support strategiesFirst-time mothersHypertensive disorders of pregnancyMedian timeHigh blood pressureHealth covariatesDisorders of pregnancyBreastfeeding initiationMother-infant dyadsMain OutcomesBreastfeeding outcomesMedicaid insuranceSupport strategiesBreastfeedingComplete dataPrescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status
Chen A, Brunetto W, Canavan M, Lipska K, Richey E, Wilson M, Zarro J, Ross J. Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status. Journal Of General Internal Medicine 2025, 1-7. PMID: 40588707, DOI: 10.1007/s11606-025-09691-4.Peer-Reviewed Original ResearchHealth maintenance organizationStaff-model health maintenance organizationArea Deprivation IndexBody mass indexLow socioeconomic statusSocioeconomic statusNon-Hispanic patientsPrescription receiptMaintenance organizationBlack patientsPatients of low socioeconomic statusHispanic patientsElectronic health record dataWhite patientsHealth record dataObesity treatmentDesignCross-sectional studyAssociation of raceHighest prevalencePrevalence of prescriptionsSelf-reported raceMain outcome measuresLogistic regression modelsObesity-related conditionsDeprivation indexProlonged Survival in Mesothelioma Patients without Surgical Resection: A National Cancer Database Analysis
Zhan P, Canavan M, Bader J, Boffa D, Resio B, Woodard G. Prolonged Survival in Mesothelioma Patients without Surgical Resection: A National Cancer Database Analysis. The Annals Of Thoracic Surgery 2025 PMID: 40588180, DOI: 10.1016/j.athoracsur.2025.06.015.Peer-Reviewed Original ResearchNational Cancer DatabaseLong-term survivalSurgical resectionOverall survivalPleural mesotheliomaClinical stage I diseaseCurative-intent surgical resectionNational Cancer Database dataNational Cancer Database AnalysisDiagnosis of malignant pleural mesotheliomaDeclined surgical resectionEpithelioid histological typeChemotherapy-treated patientsNonsurgically treated patientsStage I diseaseMalignant pleural mesotheliomaMultivariate logistic regression modelPropensity-matched cohortPropensity score matchingI diseaseSurvival benefitHistological typeSurgery 2Prolonged survivalCancer DatabaseDefinitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodSurvival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
Ayoade O, Canavan M, Caturegli G, Zolfaghari E, Resio B, Woodard G, Boffa D. Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e24041.Peer-Reviewed Original ResearchCancer patient survivalPatient survivalTumor behaviorCOVID-19 infectionCancer typesCharlson-Deyo scoreNational Cancer DatabaseSurvival of patientsKaplan Meier analysisCox proportional hazards modelsStage IV cancerAssociated with lower mortality riskProportional hazards modelCOVID-positive patientsMeier analysisCancer DatabaseLower mortality riskPositive patientsTreatment modalitiesDeyo scoreIV cancerImmune modulationImmunological consequencesCancer patientsYear mortalityThe impact of race on the association between structural racism and the quality of non-small cell lung cancer (NSCLC).
Gaddy J, Lee D, Herrin J, Yu J, Pollack C, Dean L, Hamid S, Feder S, Canavan M, Soulos P, Gross C. The impact of race on the association between structural racism and the quality of non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2025, 43: 1598-1598. DOI: 10.1200/jco.2025.43.16_suppl.1598.Peer-Reviewed Original ResearchPatient raceStructural racismNon-small cell lung cancerBlack patientsWhite patientsTwo-year survivalAppropriate evaluationSurveillance, EpidemiologyMixed effects logistic regression modelsMultivariable mixed effects logistic regression modelsEffects logistic regression modelsRegression modelsLogistic regression modelsLowest quintileHealth careRacial disparitiesRacial inequalityImpact of raceLocal stagingQuintileCell lung cancerMinoritized communitiesInteraction termsAssociationDisparities
Academic Achievements & Community Involvement
News
News
- October 22, 2025Source: Cure
Improving End-of-Life Care: Making Hospice and Home Support Accessible
- May 28, 2025
United by Cancer Research: One Mission. One Voice
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- May 17, 2024Source: NewsBreak
Most cancer treatments are useless for patients with advanced tumors near end of life